Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...
With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO ...
The earliest indicator of bladder cancer is the presence of blood in the urine. At later stages, the illness may be accompanied by pain in the flank, pelvis, and weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results